News

One of the major risk factors was a lack of follow-up healthcare services.

IgG titers were positively linked with symptom severity and certain comorbidities.

The US federal government announces plans for mRNA COVID-19 vaccine booster doses, and more children and teens are getting hospitalized for the virus.

The evolution of the major variants, including the delta mutation.

HIV risk perception and concern regarding HIV infection declined during the study.

Common cloth and surgical masks allow for the build-up of aerosol droplets over time.

A review of selected investigational long-active treatment options for HIV.

Infection preventionists at UCLA used active surveillance screening and technology to take a proactive approach to staving off any potential outbreaks of the emerging fungal infection in their health system.

While an association was found, the adverse events are very rare.

Long acting injectable PrEP therapies that are safe and effective are needed to increase options for at-risk individuals.

All Americans who received either Pfizer or Moderna will be eligible 8 months after their second dose.

Macro and micro strategies are at play in aiming to create greater PrEP access and adoption.

PrEP initiations, discontinuations and lapses all increased among Latinx patients post shelter-in-place orders.

The federal agency identified 3 more illnesses and the shrimp supplier expanded their recall.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

The interconnectedness of many healthcare facilities such as nursing homes, hospitals, and long-term acute-care hospitals means a significant chance of multidrug-resistant organism transmission when patients shuttle between facilities.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

A new study sought to approach the HIV epidemic in the United States through a distributional cost-effectiveness analysis across 6 cities.

Fewer than 10,000 adverse events among more than 8.9 million doses administered.

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

Three international trials combine data to find optimal heparin dosing against hypercoagulability and thrombosis in patients with COVID-19.

As the number of etiologies increases, we must ground our application of new diagnostic modalities with appropriate assessments.